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Abstract
Introduction Osteoarthritis (OA) is the most common form of joint disease, causing pain and disability. Previous studies 
have demonstrated the role of lipid mediators in OA pathogenesis.
Objectives To explore potential alterations in the plasma lipidomic profile in an established mouse model of OA, with a 
view to identification of potential biomarkers of pain and/or pathology.
Methods Pain behaviour was assessed following destabilisation of the medial meniscus (DMM) model of OA (n = 8 mice) 
and compared to sham controls (n = 7). Plasma and knee joints were collected at 16 weeks post-surgery. Plasma samples were 
analysed using ultra-high performance liquid chromatography accurate mass high resolution mass spectrometry (UHPLC-
HR-MS) to identify potential differences in the lipidome, using multivariate and univariate statistical analyses. Correlations 
between pain behaviour, joint pathology and levels of lipids were investigated.
Results 24 lipids, predominantly from the lipid classes of cholesterol esters (CE), fatty acids (FA), phosphatidylcholines 
(PC), N-acylethanolamines (NAE) and sphingomyelins (SM), were differentially expressed in DMM plasma compared to 
sham plasma. Six of these lipids which were increased in the DMM model were identified as CE(18:2), CE(20:4), CE(22:6), 
PC(18:0/18:2), PC(38:7) and SM(d34:1). CEs were positively correlated with pain behaviour and all six lipid species were 
positively correlated with cartilage damage. Pathways shown to be involved in altered lipid homeostasis in OA were steroid 
biosynthesis and sphingolipid metabolism.
Conclusion We identify plasma lipid species associated with pain and/or pathology in a DMM model of OA.
Keywords Osteoarthritis · Pain · LC–MS lipidomics · Destabilisation of the medial meniscus
1 Introduction
Osteoarthritis (OA) is the most common form of joint dis-
ease, characterized by pain and disability (Felson et al. 2000; 
Hinman and Crossley 2007). Recent estimates suggest that 
the global burden of knee OA affects approximately 250 
million people. In USA alone, approximately 21 million peo-
ple present with OA associated symptoms, while it is esti-
mated that the number of individuals is set to double by 2020 
(Hunter et al. 2014). Currently there are no disease modi-
fying drugs for OA and treatment of the associated pain is 
hampered by lack of efficacy and/or unwanted side-effects of 
treatments. Total joint replacement remains the most effec-
tive treatment for OA pain (Lui et al. 2015). It is increas-
ingly recognised that the slow progression of OA pathology, 
coupled with the poor relationship between radiographic OA 
and the phenotype and magnitude of pain experienced, limits 
treatment strategies to prevent the development of chronic 
pain. Biochemical markers (in blood, urine or synovial fluid) 
of OA have the potential to reflect changes in joint structure 
to monitor disease progression (Lotz et al. 2013) and OA 
pain (Valdes et al. 2017, 2018). There is a pressing clinical 
need for biomarkers of OA that detect the disease in its early 
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stages, where progression of disease may still be responsive 
to pharmacotherapy. Such biomarkers could also contribute 
to personalized medicine and the identification of new drug 
targets (Mobasheri and Henrotin 2015).
The role of a broad spectrum of lipid mediators, includ-
ing fatty acids, sphingolipids, and eicosanoids in cartilage 
degradation in OA is increasingly recognised (Masuko et al. 
2009). Lipid dysregulation in all compartments of the joint 
is considered an important feature of this disease (Cour-
ties et al. 2015; Sun et al. 2016). Lipidomics, which can be 
defined as the system-wide characterization of lipids and 
their interaction with other biochemicals and cells (Spener 
2003), has dramatically advanced over the past decade, due 
to developments in analytical technologies, such as mass 
spectrometry (MS) and chromatography, reviewed in (Hyo-
tylainen and Oresic 2016).
Previous studies highlight the value of a lipidomic 
approach to identify potential biomarkers of OA pain and 
pathology. For example, a global lipidomic analysis of 
human synovial fluid identified changes in 66 phospholipid 
species in early OA versus late OA (Kosinska et al. 2013) 
and changes in the synovial fluid levels of 21 sphingolipids 
in early OA compared to late OA (Kosinska et al. 2014). 
Comparison of the synovial fluid lipidomes of human OA 
versus canine OA identified similarities in the lipid composi-
tion between the two species, in particular for early stages of 
OA (Kosinska et al. 2016). However, collection of synovial 
fluid is invasive and there are limitations in obtaining syno-
vial fluid samples from control healthy volunteers. The util-
ity of plasma to search for biomarkers of OA progression has 
been highlighted by the first untargeted (global) lipidomics 
study of human OA plasma (Castro-Perez et al. 2010), which 
revealed an altered lipid metabolism associated with OA.
Animal models of OA have advanced understanding of 
the mechanisms of pain and facilitate studies of the complex 
relationship between pathology and pain behaviour (Little 
and Zaki 2012). Destabilization of the medial meniscus 
(DMM) in the mouse (Glasson et al. 2007) is a slowly pro-
gressing surgical model of OA, which mimics key features 
of the clinical pathology and pain responses. There are few 
lipidomic studies in animal models of OA and these have 
been focused on targeted lipid (oxylipin) analysis. In a model 
of inflammatory arthritis, He et al. (He et al. 2015) reported 
differences in oxylipin plasma levels in collagen induced 
arthritis (CIA) mice compared to control mice using a tar-
geted LC–MS/MS oxylipin method with both univariate and 
multivariate analysis. Previously we used a novel targeted 
oxylipin LC–MS/MS method to measure oxylipin and endo-
cannabinoid profiles in different tissues from the rat mono-
sodium iodoacetate (MIA) model of OA pain, compared to 
control rats (Wong et al. 2014).
The aim of the present study was to use untargeted lipid-
omics LC–MS analysis in conjunction with multivariate and 
univariate analysis to identify potential changes in plasma 
lipidome in the DMM model of OA, to identify related 
pathways of lipid metabolism altered in OA, and to inves-
tigate potential correlations with pain behaviour and joint 
pathology.
2  Material and methods
2.1  Reagents and materials
A Milli-Q water purification system (Millipore, MA, USA) 
was used in the preparation of deionized water (18.2 MΩ). 
Acetonitrile and chloroform were HPLC grade purchased 
from Fischer Scientific (Loughborough, UK). Methanol 
(LC–MS grade) and ammonium acetate were purchased 
from Sigma-Aldrich (Dorset, UK). Isopropanol (LC–MS 
grade) was obtained from Fischer Scientific (Loughborough, 
UK).
2.2  Animals
Experiments were performed on male C57BL/6 mice 
(Charles River, Margate, Kent, UK) aged 8–9 weeks at start 
of surgery in accordance with the UK Animal (Scientific 
Procedures) Act (1986). All procedures were approved by 
the University of Nottingham Ethical Review Committee 
and IASP guidelines. All animals were group-housed in a 
temperature-controlled environment (22 ± 1 °C) and main-
tained on a 12-h light/dark cycle with access to an identical 
diet and water ad libitum. A total of 15 male C57BL/6 mice 
(n = 7 in sham control group, n = 8 in DMM group) were 
used for this study.
2.3  Induction of DMM model
The surgery to generate the DMM model of OA was per-
formed under brief isoflurane anaesthesia. An incision was 
made over the medial meniscus; a blunt dissection was then 
used to open the knee joint capsule and the mediomenis-
cotibial ligament (MMTL) was transected to destabilise the 
medial meniscus (Glasson et al. 2007). Sham operated mice 
underwent the same procedure except for the transection of 
the MMTL.
2.4  Pain behaviour testing
Changes in weight distribution (weight bearing, WB) 
between the left (ipsilateral) and right (contralateral) knees 
were assessed using an incapacitance meter (Linton Instru-
ments UK) as previously described (Bove et al. 2003). Hind-
paw withdrawal thresholds (PWT) to mechanical stimulation 
of the hindpaw were measured using calibrated von Frey 
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monofilaments using the up down method, as previously 
described (Sagar et al. 2010). The timeline of behavioural 
pain measurements is provided in Electronic Supplementary 
Information (ESI, Fig. S1A). The time-course of changes in 
WB and PWT in DMM mice is provided in Figs. S1B, C.
2.5  Joint pathology
The ipsilateral knee joints were fixed in 10% neutral buffered 
formalin post-mortem before being decalcified in a 10% eth-
ylenediaminetetraacetic acid (EDTA) solution for 10 days. 
Coronal sections (5 µm thickness) were stained with haema-
toxylin and eosin before chondropathy in the medial tibial 
plateau was scored according to the OARSI scoring system 
(Glasson et al. 2010), (Fig. S2).
2.6  Plasma collection and lipid extraction
On post-operative (PO) day 112, following the last set of 
pain behaviour tests, mice were euthanized. Blood was col-
lected, centrifuged at 15,871×g for 5 min, at room tempera-
ture, and the plasma frozen immediately in liquid nitrogen. 
Note the volume of blood (1 mL) required for the global lipi-
domic analysis prevented a longitudinal study of the poten-
tial changes in lipidomics over the time-course of the study. 
For this reason we focused on the late time point (week 16) 
when pain behaviour had been significant for a number of 
weeks and joint pathology was known to be significant as 
well. All samples were stored at − 80 °C until lipidomic 
extraction (Folch et al. 1957) (see ESI) and LC–MS analysis.
2.7  Liquid chromatography–mass spectrometry 
lipidomic analysis
LC–MS analysis was performed based on a method previ-
ously published from our group (Haoula et al. 2015). Briefly, 
chromatographic separations were performed on an ACE 2 
C18 HPLC column (20 × 2.1 mm, 2 μm particle size; Aber-
deen, UK), maintained at a temperature of 40 °C and a flow 
rate of 600 µL/min. Mobile phases consisted of (A) 60:40 
acetonitrile:10 mM aqueous ammonium acetate and (B) 
90:10 isopropanol:10 mM ammonium acetate in acetonitrile. 
A binary gradient from 32 to 97% B was used with a total 
run time of 4 min. The injection volume was 10 µL and was 
the same as the mobile phase A composition.
Mass spectrometry was performed on an Orbitrap 
Exactive MS (ThermoFisher Scientific, Hemel Hempstead, 
UK) acquiring data simultaneously in full scan ion mode 
(m/z 100–1200, resolution 50,000 at m/z 200) in positive 
and negative ionisation modes. The capillary voltage was 
maintained at 25 V in the positive ion mode and at 27 V in 
the negative ion mode. The voltages of tube lens and skim-
mer in positive mode were set to 115 and 22 V respectively. 
Negative mode voltages of tube lens and skimmer were set 
to 140 and 28 V respectively. The flow rates of sheath gas, 
auxiliary gas and sweep gas for both positive negative modes 
were adjusted to 30, 15 and 5 (arbitrary units). The capillary 
temperature and heater temperature were maintained at 350 
and 300 °C respectively in both positive and negative modes.
2.8  Lipidomics data analysis
Raw UHPLC-HR-MS data from the DMM and control 
mice samples were acquired using Xcalibur v2.1 software 
(Thermo Scientific, Hemel Hempstead UK). The full data-
sets from DMM group and control group were imported and 
pre-processed in SIEVE (Version 2.1, Thermo Fisher Sci-
entific Inc., USA) using normalisation to total ion intensity 
(TIC). Ions imported for further analysis into SIMCA-14 
(Umetrics, Umea, Sweden) were included as follows: (a) 
ions with non-zero peak areas with an RSD of peak areas 
less than 30% in QCs and (b) ions that have an RSD of peak 
areas less than 30% in each group (control and OA) (Gika 
et al. 2016; Vorkas et al. 2015).
The processed datasets analysed by principal component 
analysis (PCA) and orthogonal projections to latent struc-
tures discriminant analysis (OPLS-DA) (Trygg et al. 2007) 
using pareto (Par) scaling. VIP (Variable Importance in the 
Projection) and p(corr) were used (V-Plot) to find statisti-
cally changed ions (Chang et al. 2017). Ions with VIP > 1.5 
and p(corr) > |0.4| were subjected to univariate analysis 
with False Discovery Rate (FDR) at 5% level for correction 
of multiple comparisons using Prism v.7 (Graph Pad, San 
Diego, California, USA). The performance of the analyti-
cal method was validated by monitoring a representative set 
of plasma lipids in pooled quality control (QC) samples, 
injected throughout the LC–MS (following full equilibra-
tion) run to assess RSD(%) of retention time (RT) shifts and 
peak areas.
Tentative identification of significant lipids was achieved 
by using accurate mass determinations (up to 5 ppm mass 
accuracy) to search appropriate metabolite databases: LIPID 
MAPS (www.lipid maps.org), the Human Metabolome data-
base (www.hmdb.ca) and METLIN (https ://metli n.scrip 
ps.edu). Statistically significant lipid species were con-
firmed by MS/MS fragmentation experiments in Q-Exactive 
(Thermo, UK) using LipidSearch (Breitkopf et al. 2017, 
Peake et al. 2013) software v4.1 (Thermo Fisher Scientific, 
CA, USA) (see ESI for more information).
Metabolite identification confidence was classified using 
identification levels as proposed previously (Sumner et al. 
2007). Putative statistically significant lipids between sham 
and DMM groups were categorized according to their VIP 
score. Furthermore, in order to validate the differentially 
expressed lipids the sensitivity, specificity and the area under 
the receiver-operating characteristic (ROC) curve for binary 
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classification of the OPLS-DA models were also calculated 
from the respective Monte-Carlo cross validation prediction 
(www.metab oanal yst.ca).
In addition, based on the identified biomarkers, the 
plasma lipidomic pathway analysis was performed using 
Metabolic Pathway Analysis (MetPA), a tool in MetaboAn-
alyst (www.metab oanal yst.ca), to reveal the most relevant 
pathways related to OA. The impact value of these pathways 
calculated from pathway topology analysis above 0.1 was 
considered as the potential target pathway.
2.9  Statistical analysis
Statistical analysis was performed using Prism v.7 (Graph 
Pad, San Diego, California, USA). Data are presented as 
mean ± SEM or box-and-whisker plots. Changes in weight 
bearing asymmetry and log transformed paw withdrawal 
thresholds (PWT) in DMM and sham operated mice over 
time were analyzed by two-way ANOVA with Bonferroni 
corrected multiple comparisons. Differences in medial tib-
ial plateau cartilage damage between DMM and sham mice 
were analyzed by Mann–Whitney U test. Differences in lipid 
metabolite expression between DMM and sham mice were 
analyzed by two-tailed Welch’s t-test. Correlations between 
pain behavior (weight bearing asymmetry and log PWT at 
the final behavioural timepoint) and MTP cartilage damage 
with the expression of lipid metabolites were analyzed by 
Pearson’s Correlation Coefficient. A value of p < 0.05 was 
considered significant for all analyses.
3  Results
3.1  Pain behavior and joint pathology of DMM 
model
Changes in weight-bearing (WB) were evident in DMM 
mice, with a significant decrease in WB on the injured side 
from day 56 post-DMM surgery, compared with sham con-
trols. Changes in WB remained stable until the end of the 
study (Fig. S1A). Similarly, ipsilateral hindpaw withdrawal 
thresholds were lowered from day 49 post DMM surgery 
until the end of the study (Fig. S1B). There were significant 
differences in pain behavior between the DMM and sham 
control group for the later stages of the study. At the end 
of the study (day 112) DMM mice had a significant MTP 
Fig. 1  Multivariate analysis of global lipidomics in the DMM mouse 
model. a OPLS-DA score plot of plasma from DMM (n = 8, blue) 
and, sham mice (n = 7, green). The score plots show a good separa-
tion between DMM and sham mice (R2X = 0.547, R2Y = 0.794, and 
Q2 = 0.407). b V-plot with p(corr) and VIP values. Features with 
VIP > 1.5 and p(corr) >|0.4| are highlighted in red. c A permutation 
test performed with 100 random permutations on generated PLS-DA 
model; R2 is the explained variance, and Q2 is the predictive ability 
of the model. Low value of Q2-intercept depicts the high predictabil-
ity of the model
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score indicative of cartilage damage, compared to the sham 
controls (Fig. S2).
3.2  Lipidomic profiling using UHPLC‑HR‑MS 
and identification of potential biomarkers
The lipidomics analysis met accepted quality criteria 
with close clustering of the plasma QCs in PCA, and with 
RSD% of peak areas from selected lipids and RT being 
less than 15% and 2%, respectively (ESI, Table S1).
An unsupervised PCA was initially performed on the 
normalized data to identify trends in groups, clusters and 
potential outliers (ESI, Fig. S3). A supervised OPLS-
DA model was generated (Fig. 1a) where R2X = 0.547, 
R2Y = 0.794, and Q2 = 0.407 showing good prediction of 
the model (Q2 > 0.4). The set of lipids that made signifi-
cant contributions to the difference between the DMM and 
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Fig. 2  Lipids discriminating DMM samples (red) from sham samples (green). Box-and-whisker plots illustrating levels differences for the six 
lipid biomarkers between DMM and sham groups of mice. Welch’s t-test was applied. *p < 0.05; **p < 0.01
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sham mice were identified using the V-Plot (Fig. 1b). The 
OPLS-DA permutation plot had low (negative) value of 
Q2-intercept confirming validation of the original model 
(Fig. 1c). Univariate statistical analysis using FDR (at 
level of 5%) revealed 24 differentially expressed lipids 
that were tentatively identified using metabolomics and 
lipidomics databases (METLIN, LIPIDMAPS, HMDB, 
and KEGG) (Table 1). For confirmation of lipid species, 
MS/MS fragmentation experiments (with LipidSearch 
software) using a pooled QC sample (ESI, Figs. S4–9) 
confirmed the identities of six of the 24 significant lipids 
and were assigned as CE(18:2), CE(20:4), CE(22:6), 
PC(18:0/18:2), PC(38:7), and SM(d34:1). The remaining 
lipids were assigned to class of lipid and are reported as a 
specific m/z ion, with a tentative identification (Table 1). 
LipidSearch outputs for the six identified lipids are given 
in ESI (Figs. S4–9). These six potential lipid biomarkers 
belong to three different lipid classes; sterols (STs), phos-
pholipids (PLs), and sphingolipids (SLs). The tentatively 
identified lipids belong to the three aforementioned classes 
in addition to the class of fatty acids (FAs). Plasma levels 
of CE(20:4), CE(18:2), CE(22:6), PC(38:7), PC(18:0/18:2) 
and SM(d34:1) were significantly higher in the DMM 
group, compared to the sham group (Fig. 2).
3.3  Prediction and diagnostic performance test
ROC analysis was performed to validate the OPLS-DA 
analysis and test the applicability of the six identified 
lipid biomarkers in separating DMM mice and sham con-
trol. Figure 3a shows a group of ROC curves for models 
established by using different lipids selected by the filter 
approach. Five models were generated. The top two lipids 
[CE(18:2) and PC(18:0/18:2)] were used to build clas-
sification model 1; the AUC value was 0.802 and the 95% 
confidence interval (CI) was 0.306–1. When all six lipids 
were used the AUC value was 0.863, while sensitivity was 
Table 1  Identification of the 24 significant lipids (top 18 are shown) in DMM plasma (n = 7 and 8 mice/group, for sham and DMM, respectively) 
using UHPLC-HR-MS global lipidomics platform and OPLS-DA analysis
Lipids are sorted by their VIP scores (descending). Online databases METLIN, KEGG, HMDB and LIPIDMAPS were used to assign masses 
(m/z) to putative lipid species. Mass accuracy is considered less than 5 ppm. Fold change between DMM vs sham groups is shown. p values 
generated after applying FDR correction are given. Lipids identified by MS/MS experiments in Q Exactive with LipidSearch software) are high-
lighted in bold, when available. Lipid classes are also given
a DMM/sham group ratio (mean values from each group were used)
b DMM vs sham groups
c p value adjusted after FDR correction (5%) applied (GraphPrism v.6)
d Lipid abbreviations: NAE N-acylethanolamine, FA fatty acid, LCB long-chain bases, CE cholesteryl ester, PC phosphocholine, Cer ceramide, 
SM sphingomyelin
m/z MS mode Time (min) VIP Fold  changea Trendb p  valuec Putative lipid  biomarkerd Confi-
dence 
 levele
Lipid class
318.240 POS 0.32 11.0 1.27 ↑ 0.00749 NAE 16:2 3 Fatty acyl
296.258 POS 0.28 10.0 1.49 ↑ 0.00731 FA(18:3) 3 Fatty acid
369.351 POS 2.86 8.0 1.39 ↑ 0.00598 Cholesterol 3 Sterol lipid
282.279 POS 0.73 7.9 1.39 ↑ 0.00893 LCB 18:2;1 3 Sphingolipid
690.619 POS 2.81 7.2 1.37 ↑ 0.00656 CE(20:4) 2 Sterol lipid
666.618 POS 2.88 6.7 1.38 ↑ 0.00368 CE(18:2) 2 Sterol lipid
844.609 NEG 2.15 5.5 1.26 ↑ 0.0164 PC(18:0/18:2) 2 PC
613.492 POS 0.32 4.4 1.44 ↑ 0.00376 CE(14:3) 3 Sterol lipid
806.569 POS 1.45 4.4 1.17 ↑ 0.0129 PC(38:6) 3 PC
714.619 POS 2.77 4.2 1.43 ↑ 0.00841 CE(22:6) 2 Sterol lipid
804.551 POS 1.53 3.3 1.19 ↑ 0.0190 PC(38:7) 2 PC
473.401 NEG 1.37 2.8 1.07 ↑ 0.0130 Sitosterol 3 Sterol lipid
256.268 POS 0.6 2.7 1.24 ↑ 0.00797 LCB 16:1;1 3 Sphingolipid
316.321 POS 0.79 2.6 1.13 ↑ 0.0217 FA(19:0) 3 Fatty acid
700.628 POS 2.72 2.3 1.43 ↑ 0.0114 Cer 43:2;3 3 Sphingolipid
703.575 POS 1.53 2.2 1.39 ↑ 0.00680 SM(d34:1) 2 Sphingolipid
290.209 POS 0.27 1.8 1.31 ↑ 0.00866 NAE 14:2 3 Fatty acyl
326.378 POS 0.66 1.8 1.45 ↑ 0.00334 FA(22:1) 3 Fatty acid
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100%, specificity of 85.7% (Fig. 3d), and predictive accu-
racy of 78.8% (Fig. 3b). On the basis of the selected bio-
markers, ROC analysis revealed that the OPLS-DA model 
identified lipid biomarkers, sorted by their importance 
(Fig. 3c), that account for the differences between control 
and DMM mice.
3.4  Metabolic pathway analysis
The six lipids identified as potential biomarkers of OA 
were related to steroid (i.e. cholesterol) biosynthesis (CEs), 
sphingolipid metabolism [SM(d34:1)], linoleic acid, alpha-
linolenic acid, glycerophospholipid, and arachidonic acid 
metabolism [PC(18:0/18:2) and PC(38:7)] (Fig. 4). The 
pathway with the smallest p value (p < 0.05) is considered 
the metabolic route most significantly altered in the DMM 
OA model. Notably, p values (raw p values) for all path-
ways generated from Metaboanalyst were p < 0.05. For more 
details see (ESI, Table S2).
3.5  Correlation analysis of lipid levels with pain 
behaviour and joint pathology
Pain on loading (weight-bearing asymmetry) and cartilage 
damage were not correlated with each other (ESI, Fig. 
S10). A Pearson correlation analysis evaluated potential 
associations of the six plasma lipids and pain behaviour 
parameters (WB and PWT). Plasma levels of CE(18:2), 
CE(20:4), CE(22:6), and PC(38:7) were positively cor-
related with changes in WB (p < 0.05, Fig. 5). There was 
Fig. 3  Comparison of different variables based on ROC curves a 
the legend shows the feature numbers and the AUCs of the five 
models, b the predictive accuracies with different features based on 
ROC curves, c the average importance of six lipids based on ROC 
curves, in descending order of importance, and d prediction of DMM 
and sham mice using MCCV analysis. The prediction of the model 
depends on the area under the curve (AUC) provided by ROC analy-
sis: the greater the AUC, the better the prediction of the model
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a similar trend for PC(18:0/18:2) and SM(d34:1) (Fig. 5). 
There was a significant negative correlation between 
PWTs and plasma levels of CE(18:2), CE(20:4), CE(22:6), 
and PC(18:0/18:2) (Fig. 6). There was a similar trend for 
PC(38:7) and SM(d34:1) (Fig. 6). It is important to note 
that an increase in WB is indicative of pain behaviour, 
whereas a lowering of PWT is also indicative of pain 
behaviour. Overall CE(18:2), CE(20:4), and CE(22:6) 
levels were significantly correlated with both features of 
pain behaviour, suggesting that these plasma lipids may 
be biomarkers of OA pain behaviour. Lastly, all of the 
lipids with the exception of PC(38:7) were positively and 
significantly correlated with cartilage damage (Fig. S11). 
4  Discussion
4.1  Lipid biomarkers of potential biological 
significance
The present study identified six potential plasma lipid 
biomarkers in the DMM model of OA pain, which were 
related to steroid biosynthesis (three CEs), sphingolipid 
metabolism [SM(d34:1)], linoleic acid, alpha-linolenic 
acid, glycerophospholipid, and arachidonic acid metab-
olism [PC(18:0/18:2) and PC(38:7)]. Although the fold 
changes of individual lipid levels between the sham and 
DMM mice were small (less than twofold), combining 
these six lipids together provided a valid model of OA 
pathology and pain as indicated by the ROC analysis 
(Fig. 3). Our data are supported by reports that the meta-
bolic pathways underpinning the generation of these six 
lipids play important roles in OA pathogenesis, reviewed 
in (Masuko et al. 2009).
Sphingolipids (SLs) are a class of lipids that include 
ceramide (Cer) species, sphingomyelins (SMs) and more 
complex glycosphingolipids known to be present in SF 
(Lahiri and Futerman 2007). SLs are structural components 
of plasma membranes and bioactive molecules that regulate 
many processes including growth and differentiation, cellu-
lar signal transduction, and apoptosis in cells such as fibro-
blast-like synoviocytes (FLSs) (Baker et al. 2011; Patward-
han et al. 2016). Changes in sphingolipid metabolism have 
been associated with joint damage in a model of OA and 
selective inhibition of sphingosine kinase-2, a key enzyme 
in the sphingolipid pathway, attenuated histological dam-
age and pain behaviour associated with MIA-induced OA 
in rats (Fitzpatrick et al. 2011). Our report that SM(d34:1) 
is a potential plasma lipid biomarker of OA is in agreement 
with a report by Kosinska et al. (2014) that the levels of 
19 SMs, including SM(d34:1), were approximately twofold 
higher concentrations in SF from late OA versus early OA 
in humans. Furthermore, levels of 6 SMs were statistically 
increased by 1.7 fold in SF in a sub-group of OA sufferers 
(Zhang et al. 2014). Consistencies between the changes in 
the lipidome in plasma and SF in OA support further inves-
tigation of SLs as potential of plasma biomarkers.
Phospholipids (PLs) are essential components of all 
biological membranes and they contribute to boundary 
lubrication that is provided by SF (Kosinska et al. 2015). 
Our demonstration that plasma levels of PC(18:0/18:2) 
and PC(38:7) are significantly higher in the DMM model 
of OA are consistent with previous clinical data (Kosinska 
et al. 2013) showing alteration of phospholipid species 
between early OA and late OA SF in humans. The group 
of Kosinska (Kosinska et al. 2013) suggests that the phos-
pholipid composition in SF is associated with increased 
friction, inflammation, and cartilage damage, ultimately 
reflecting the severity of human OA. A separate study 
demonstrated that levels of 24 glycerophospholipids in SF 
were significantly higher in patients in a subgroup of OA 
sufferers, with this effect more prominent for PC species 
(Zhang et al. 2014).
Amongst the significant lipids that were found to separate 
sham from DMM mice were NAE (14:2) and NAE (16:2). 
These lipids belong to the class of N-acylethanolamines 
(NAEs), bioactive lipids involved in many physiological 
processes including pain and inflammation (Bottemanne 
et al. 2018; Tsuboi et al. 2018).
Linoleic acid (18:2), an omega-6 fatty acid, which is a 
constituent part of two of our identified lipid biomarkers 
Fig. 4  Summary of pathway analysis with MetPA: (a) steroid biosyn-
thesis, (b) sphingolipid metabolism, (c) linoleic acid metabolism, (d) 
alpha-linolenic acid metabolism, (e) glycerophospholipid metabo-
lism, and (f) arachidonic acid metabolism. The pathways depicted are 
listed from (a) to (f) in a descending order of importance, based on a 
combination of both the p values (y-axis) and impact (x-axis), accord-
ing to Metabolic Pathway Analysis (MetPA) carried out in Metabo-
analyst
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CE(18:2) and PC(18:0/18:2), is known to be metabolised 
via lipoxygenase, cyclooxygenase and cytochrome P450 
(CYP) enzymes to a range of hydroxy- and oxo- metabo-
lites that exhibit anti-inflammatory and immunomodulatory 
properties in OA (Chabane et al. 2009). Relevant to this 
observation, our group has recently reported that omega-6 
FAs are increased in OA joints and downstream products 
of linoleic acid are associated with radiographic progres-
sion of OA (Valdes et al. 2018). The steroid biosynthesis 
pathway, identified in our study, has an important role in 
joint homeostasis, reviewed here (Farnaghi et al. 2017a, b), 
with both cartilage and bone severely affected by steroid 
hormone glucocorticoids, which are frequently used to treat 
inflammatory diseases.
Although identities were not confirmed for the lipids 
in the class of fatty acids (FAs), this family of lipids has 
established roles in OA (Sekar et al. 2017; Thomas et al. 
2018). Recent studies support an involvement of n-3 poly-
unsaturated fatty acids (PUFAs) and their anti-inflamma-
tory and pro-resolving derivatives in OA. These lipids were 
identified in the OA joint, and were found to have benefi-
cial effects on cartilage health in vitro and reduced pain in 
human OA and animal models (Mehler et al. 2016; Van de 
Vyver et al. 2018), reviewed here (Ioan-Facsinay and Klop-
penburg 2018).
4.2  Correlation analysis of lipids with pain 
and histology parameters
Potential relationships between levels of plasma lipid bio-
markers and pain parameters (WB and PWT) at 16 weeks 
post-surgery were determined. Levels of the six plasma 
Fig. 5  Correlation between 
levels of lipid metabolites and 
weight bearing asymmetry 
(WB) 16 weeks post DMM/
sham surgery. Data analysed 
by Pearson’s Correlation Co-
efficient. A positive correlation 
for all lipid biomarkers was 
observed. P and r values are 
shown
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lipids identified as being elevated in the DMM model were 
significantly associated with pain behavior in the model of 
OA at this time-point. These data strengthen the validity of 
these six plasma lipids as potential biomarkers for estab-
lished OA pain and are in agreement with the demonstration 
that increased levels of cholesterol transport molecules are 
associated with inflammation and pain in animal models of 
OA (Ioan-Facsinay and Kloppenburg 2018). However, it is 
still unknown whether these plasma lipids are related to pain 
during the onset and development of pain over time. Simv-
astatin, a lipid-lowering agent that blocks the production of 
cholesterol, inhibited mechanical hyperalgesia in a model of 
neuropathic pain, as well as attenuating the development of 
morphine tolerance (Vieira et al. 2017). In our study, plasma 
levels of the three CEs, PC(18:0/18:2), and SM(d34:1) 
which were significantly elevated in the DMM model, were 
correlated with the extent of articular cartilage damage in 
the knee joint at 16 weeks post-surgery. These data are con-
sistent with evidence that a cholesterol-rich diet increased 
cartilage damage in a collagenase mouse model of OA (de 
Munter et al. 2013). In addition, mice fed a high-cholesterol 
diet had greater breakdown of the cartilage matrix compared 
to controls (Farnaghi et al. 2017a, b) and that the severity 
of diet-induced OA changes were attenuated by treatment 
with atorvastatin, a statin. In our study, both groups of mice 
followed the same diet and subsequently had the same cho-
lesterol intake, hence any changes in cholesteryl esters (CEs) 
levels could be due to changes in cholesterol ester metabo-
lism in the OA mouse model. More research into the role of 
CEs in OA pathophysiology is needed to further support our 
findings. Lastly, levels of both phospholipids (McDougall 
et al. 2017) and sphingomyelins (Kosinska et al. 2013) were 
Fig. 6  Correlation between lev-
els of lipid metabolites and log 
transformed ipsilateral hindpaw 
withdrawal thresholds 16 weeks 
post DMM/sham surgery. Data 
analysed by Pearson’s Correla-
tion Co-efficient. A negative 
correlation for all lipid biomark-
ers was observed. P and r values 
are shown
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correlated with cartilage damage in the MIA model of OA in 
the rat and in human OA patients, respectively.
5  Conclusions
This is the first study using global LC–MS based lipidomics 
analysis in the established DMM mouse model of OA. Our 
LC–MS analysis of the whole lipidome in the plasma indi-
cated differences in the profiles of 24 lipids between DMM 
and sham mice. Evidence is presented that a panel of six 
fully identified lipid species consisting of CEs, SMs and PCs 
may play roles in the pathogenesis of OA like chondropathy 
in this model. The six potential lipid biomarkers were related 
to different biochemical pathways, mainly steroid biosyn-
thesis, sphingolipid and glycerophospholipid metabolism, 
consistent with previous studies. Lastly, correlation analysis 
suggests that the three CEs identified here are strongly asso-
ciated with pain behavior and cartilage damage in the DMM 
model. While the findings need to be confirmed in large 
clinical studies in human knee OA, the identification of these 
six lipid biomarkers in small rodent studies in a non-invasive 
biological source, such as plasma, will help to unravel the 
pathogenesis and develop targeted therapies for OA.
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